BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic assay

The purpose of the study is to validate the effectiveness of the test methods developed by DiagnosTear in the tears of healthy subjects as well as patients with Dry Eye Syndrome.

Suzana Nahum-Zilberberg, BioLight’s CEO, said, "The beginning of DiagnosTear clinical study is an additional development milestone in one of the most promising projects in our XLVision Sciences cluster. About 100 million people worldwide suffer from Dry Eye Syndrome and many more suffer from similar symptoms. A significant improvement in the diagnosis of the Syndrome is needed and DiagnosTear provides a very promising assay that assists physicians in diagnosing the Syndrome, selecting the right treatments and monitoring progress."

Ms. Nahum-Zilberberg added, "A market analysis performed among U.S. ophthalmologists shows that the assay DiagnosTear develops as a multi-parameter, cost-effective and easy-to-use solution is designed to meet those needs. This clinical study, which we expect will start in the coming days, is another significant step in the development process. We note that this diagnostic assay has stimulated strong interest among leading ophthalmic companies and key opinion leaders worldwide."

DiagnosTear is preparing to add another center in Israel to the clinical study soon and expects to report its results in the fourth quarter of 2014.